Search Within

Neal Rosen

Formats
  1. Journal Article (226)
  2. Meeting Abstract (186)
  3. Conference Paper (7)
  4. Book Section (2)
  5. Editorial (2)
  6. Review (2)
  7. Research Letter (1)
Groups
  1. Breast Medicine Service (426)
  2. Department of Medicine (426)
  3. GSK Faculty (426)
  4. Molecular Pharmacology and Chemistry Program Faculty (426)
  5. Sloan Kettering Institute Faculty (426)
  6. Solid Tumor Oncology Division (426)

More Groups

People
  1. David Solit (155)
  2. Sarat Chandarlapaty (57)
  3. Howard Scher (44)
  4. Christine Pratilas (36)
  5. Elisa De Stanchina (36)
  6. Laura Sepp-Lorenzino (36)

More People

Years
  1. 2025 (2)
  2. 2024 (6)
  3. 2023 (2)
  4. 2022 (13)
  5. 2021 (13)
  6. 2020 (12)

More Years

Publications
  1. Cancer Research (99)
  2. Clinical Cancer Research (43)
  3. Proceedings of the American Association for Cancer Research Annual Meeting (36)
  4. Cancer Discovery (24)
  5. Journal of Clinical Oncology (23)
  6. Cancer Cell (15)

More Publications

Publishers
  1. American Association for Cancer Research (212)
  2. Nature Publishing Group (38)
  3. American Society of Clinical Oncology (24)
  4. Cell Press (19)
  5. Elsevier Inc. (17)
  6. National Academy of Sciences (11)

More Publishers

Results (426)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Borwick, L. S.; Momen, L.; Curley, T.; Arauz, G.; Larson, S. M.; Fleisher, M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer
    Meeting Abstract

    Gajria, D.; King, T. A.; Pannu, H.; Sakr, R.; Seidman, A. D.; Syldor, A.; Patil, S.; Maybody, M.; Norton, L.; Rosen, N.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • mTOR kinase inhibition relieves feedback inhibition of RTK and PI3K signaling in breast cancer cells
    Meeting Abstract

    Rodrik-Outmezguine, V. S.; Chandarlapaty, S.; Cao, N.; Smith, P.; Guichard, S.; Rosen, N.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • MEK inhibitors prevent rebound reactivation of ERK signaling by the RAF inhibitor PLX4032 and enhance its antitumor activity
    Meeting Abstract

    Pratilas, C. A.; Joseph, E. W.; Tadi, M.; Gabay, M.; Wong, W.; De Stanchina, E.; Bollag, G.; Rosen, N.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Can PI3K/AKT pathway mutations predict for type of recurrence after conservative treatment for DCIS
    Meeting Abstract

    Sakr, R. A.; Andrade, V. P.; Muhsen, S.; Chandarlapaty, S.; Giri, D.; Olvera, N.; Paik, W.; Goldberg, J. I.; Van Zee, K. J.; Rosen, N.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • An in-frame deletion in the N-terminal regulatory domain of BRAF(V600E) causes resistance to the RAF inhibitor PLX4032
    Meeting Abstract

    Poulikakos, P. I.; Persaud, Y.; Gabay, M. T.; Janakiraman, M.; Joseph, E. W.; Pratilas, C. A.; Chapman, P. B.; Rosen, N.; Solit, D. B.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Activating MEK1(F129L) mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation
    Meeting Abstract

    Niu, H. F.; Wang, H. S.; Daouti, S.; Li, W. H.; Wen, Y.; Rizzo, C.; Higgins, B.; Packman, K.; Rosen, N.; Boylan, J. F.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • CH5126766 is a novel allosteric inhibitor of MEK that prevents its phosphorylation by RAF
    Meeting Abstract

    Ishii, N.; Harada, N.; Sakamoto, H.; Matsuda, Y.; Tomii, Y.; Tachibana-Kondo, Y.; Miura, T.; Ohara, K.; Iikura, H.; Aoki, T.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Inhibition of PI3K-AKT signaling causes a FOXO-dependent induction of receptor tyrosine kinase expression and phosphorylation in cancer
    Meeting Abstract

    Chandarlapaty, S.; Sawai, A.; Rodrik-Outmezguine, V.; Scaltriti, M.; Serra, V.; Baselga, J.; Rosen, N.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save